BioStock: Ultimovacs receives Orphan Drug Designation from EMA

Ultimovacs has been granted Orphan Drug Designation from the European Medicines Agency for its universal cancer vaccine, UV1, as a treatment for mesothelioma, a rare and aggressive form of cancer with limited therapeutic options. The designation was granted based on results from the phase II clinical trial NIPU and brings regulatory and commercial benefits to the development of the immunotherapy. BioStock reached out to CEO Carlos de Sousa for a comment.

Read the interview with Carlose de Sousa at biostock.se:

Ultimovacs receives Orphan Drug Designation from EMA - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/